Navigation Links
ECNP expresses concern at AstraZeneca neuroscience pull-out
Date:2/6/2012

The European College of Neuropsychopharmacology expresses its deep concern at the recently announced withdrawal by AstraZeneca from neuroscience drug research. AstraZeneca's pull-out is especially disturbing given that it follows a series of similar withdrawals in the last two years by major pharmaceutical companies. There is a growing sense that neuroscience in Europe is now facing a severe crisis.

"Disorders of the brain are Europe's pre-eminent health care concern of the future," says ECNP president, Joseph Zohar, professor of psychiatry at Tel Aviv University. "Medications, properly targeted, are in almost all cases the key to effective treatment. To have a major player like AstraZeneca, with an outstanding history of innovation and development in disorders of the brain, pull out of the field in this way will inevitably affect Europeans' access to high-quality medications in the future. This is not good news for patients."

Research sponsored by ECNP shows that more than a third of all Europeans experience some form of mental disorder in any given year, at a total cost to the region of some 800 billion per annum. The direct medical costs of these disorders constitute almost a quarter of the European Union's total health care expenditure, with indirect costs from work absences to enforced early retirement almost twice as much again. The social and emotional costs are incalculable.

AstraZeneca's pull-out is especially disturbing given that it follows a series of similar withdrawals in the last two years by major pharmaceutical companies, including GlaxoSmithKline, Pfizer, Merck, Sanofi and Novartis, who have all significantly downsized their neuroscience commitment. There is a growing sense that neuroscience in Europe is now facing a severe crisis.

"Neuroscience has long been one of Europe's outstanding scientific strengths," says ECNP secretary, Sven Ove gren, professor of neuroscience at Sweden's Karolinska Institutet. "The loss of hundreds of research positions in the field is an enormous blow. Coming on top of similar closures at almost all of Europe's big pharma companies, it's a very worrying development. What's now urgently needed is united action from all those interested in Europe's neuroscientific future to ensure that the region's neuroscience research base of which pharma is an indispensible part does not suffer permanent and possibly irreversible damage."


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
43-140-55734
European College of Neuropsychopharmacology
Source:Eurekalert

Related medicine news :

1. Supportive of intent of ACO proposed rule, ACP expresses concern
2. IHRSA Expresses Its Ardent Support of America's First-Ever National Physical Activity Plan and Accepts Role as Co-Chair of Implementation Sub-Committee
3. U.S. African Chamber of Commerce President Expresses Concern over Health Care Bill
4. Cases of Tamiflu-Resistant Flu Concern Experts
5. Women should still be concerned about hormone replacement therapy, say McMaster researchers
6. Buildup of Newer Flame Retardants Concerns Scientists
7. Potential concern about drugs in clinical trial
8. Group sex among adolescents a public health concern, new study says
9. 15 new conservation concerns
10. Concerns about teen sexting overblown, according to new UNH research
11. Internists address dual concerns of privacy and protection of health data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 26, 2017 , ... Today, A' Design Awards & Competition ... Social Design Awards. , The 7th A' Social Design Award is open ... worldwide with realized projects and conceptual works. , The first phase of the ...
(Date:2/26/2017)... , ... February 26, 2017 ... ... a new technology standard in staffing, scheduling, and reporting for healthcare organizations. ... predict activity throughout the entire staffing process. StaffBridge technology improves staffing efficiency, ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... newly designed TaskMate Go. Core benefits and advantages built into the home office ... stylish, functional look and feel. Ability to gain the benefits embedded in the ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Liberty University, has officially announced the appointment of Peter A. Bell, DO, MBA, ... Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty from ...
(Date:2/24/2017)... ... 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ... his paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles ... , Schanssema, initially unsure of the career path he wanted to take, found fulfillment ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb 27, 2017 Period October – December 2016 ... Operating result amounted to SEK -16.4 (-6.4) million Result after ... (-0.22) before and after dilution Cash flow from operating activities ... ... 0.4 (0.4) million Operating result amounted to SEK -39.5 (-29.5) ...
(Date:2/24/2017)... , Feb. 24, 2017 Research and ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... a CAGR of around 23.8% over the next decade to reach ... the market estimates and forecasts for all the given segments on ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies ... eye market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Dry eye ...
Breaking Medicine Technology: